What is the difference between medical weight loss and just buying a GLP-1?

Medical weight loss is a supervised program: a clinical evaluation, a prescription chosen for your situation, ongoing monitoring of dose and side effects, and lifestyle support. NIDDK treats the medication as an addition to diet and activity, not a substitute. Buying a drug with no evaluation, no licensed pharmacy, and no follow-up is a transaction, not care — and often a safety risk.

Do I qualify for FDA-approved weight-loss medication?

The FDA label criteria are a BMI of 30 or higher, or a BMI of 27 or higher combined with at least one weight-related condition such as high blood pressure, abnormal cholesterol, or type 2 diabetes. A prescriber applies these to your actual measurements and history. BMI is a screening tool, so the clinical evaluation still governs the final decision.

Which weight-loss drug is right if I take birth control pills?

This is a real point of difference. Tirzepatide (Zepbound and Mounjaro) can reduce oral contraceptive effectiveness according to its FDA label, and the labeling advises extra contraceptive precautions after starting and after dose increases. Semaglutide (Wegovy and Ozempic) does not carry that warning. Raise your contraception with a prescriber before choosing — an unsupervised seller will not flag it.

How much does a medical weight-loss program cost?

There is no single price. Cost depends on your payment path: insurance coverage, a manufacturer savings card, manufacturer self-pay, cash at a pharmacy, or a non-FDA-approved compounded product. Because manufacturers change prices, the only reliable current figure comes from the drug maker's own savings page — Lilly for Zepbound and Mounjaro, Novo Nordisk and NovoCare for Wegovy and Ozempic.

Can these medications help with PCOS or perimenopause weight gain?

PCOS often involves insulin resistance, which the GLP-1 class acts on, and perimenopause shifts fat storage and metabolism. The drugs are FDA-approved for weight management or diabetes, not for PCOS or menopause specifically, so any such use is a clinical decision by your prescriber. Hormone therapy, per ACOG, manages menopause symptoms and is not a weight-loss treatment; coordinate these decisions with clinicians who see the full picture.

Can I get weight-loss medication online without a prescription?

No — and any site offering it without one is a warning sign. The legitimate telehealth path requires a consult with a clinician licensed in your state and dispensing through a licensed pharmacy. The FDA has warned about counterfeit and unapproved GLP-1 products sold outside the legal supply chain. No prescription, no licensed pharmacy, or unclear shipping origin means treat it as a safety risk, not a deal.

Is Ozempic or Mounjaro approved for weight loss?

No. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, so using either for weight loss alone is off-label. The FDA-approved weight-management versions are Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Off-label use is legal but affects insurance coverage and eligibility for manufacturer savings programs, so ask a provider exactly which product they mean.

Weight · Medical program

Medical Weight Loss for Women: Programs, Prescriptions, and Cost

Educational guide · By ClearHormones Editorial Team · Updated July 2026

Medical weight loss for women is a physician-supervised program that pairs a clinical evaluation with a prescription anti-obesity medication when appropriate, ongoing monitoring of your response and side effects, and structured lifestyle support. It is distinct from over-the-counter supplements and generic diet plans because a licensed prescriber assesses your eligibility, orders labs, chooses a drug with an FDA-approved indication that fits your situation, and adjusts the plan over time. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) frames prescription obesity medicine as an addition to diet, physical activity, and behavior change, not a replacement for them.

Key takeaways

A medically supervised program has four parts: evaluation and labs, a prescription when clinically appropriate, ongoing monitoring, and lifestyle support — NIDDK treats the drug as an addition to diet and activity, not a substitute.
Wegovy and Zepbound are FDA-approved for chronic weight management; Ozempic and Mounjaro are approved for type 2 diabetes, so using them for weight alone is off-label.
FDA label eligibility is a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes.
Cost is not one number — it depends on whether you use insurance, a manufacturer savings card, manufacturer self-pay, cash at a pharmacy, or a non-FDA-approved compounded product. Verify live prices on the manufacturer's own savings page.
Tirzepatide (Zepbound and Mounjaro) can reduce oral contraceptive effectiveness; semaglutide does not carry that warning — a real difference for women using the pill.
Legitimate telehealth requires a prescriber consult and a licensed pharmacy. Any site offering these drugs with no prescription is a red flag for counterfeit or unapproved product.

The short answer

For most women researching this today, the practical question is: what does a real program include, who qualifies, how do you access it through telehealth, and what will it cost. The short version is that FDA-approved options such as Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are indicated for chronic weight management when your BMI meets the label criteria, telehealth platforms connect you to a prescriber licensed in your state and route any prescription to a licensed pharmacy, and cost depends heavily on which payment path applies to you: insurance coverage, a manufacturer savings card, manufacturer self-pay, cash at a pharmacy, or a compounded product that is not FDA-approved.

Women's hormonal biology also shapes the picture in ways a generic weight-loss page ignores. Perimenopause shifts fat storage and metabolism, PCOS ties weight to insulin resistance, and tirzepatide carries an oral-contraceptive interaction that semaglutide does not. This page walks through each layer so you can compare providers with a clear head. Our site does not sell or prescribe medication; the goal here is to help you understand the category before you compare providers licensed in your state.

What a medically supervised weight-loss program actually includes

A genuine medical weight-loss program has four moving parts, and a provider missing any of them is worth questioning. The first is a clinical evaluation: your weight history, current medications, personal and family medical history, and often baseline labs. This is where a prescriber confirms whether an anti-obesity medication is appropriate and safe for you, or whether an underlying issue such as thyroid disease is driving the weight.

The second part is the prescription itself, chosen to match your clinical picture and the drug's approved use. NIDDK is explicit that these medications are meant to be used alongside reduced-calorie eating and increased physical activity, not instead of them. A prescriber who writes a script without any plan for diet, activity, or follow-up is delivering a product, not a program.

The third part is monitoring. GLP-1 and GIP/GLP-1 medications are titrated upward over weeks to limit nausea and other gastrointestinal effects, and a supervising clinician tracks your response, side effects, and whether the dose should hold or advance. The fourth part is lifestyle support — nutrition guidance, activity, and behavior change — which is what turns short-term appetite suppression into durable results and what protects muscle as you lose weight.

For women specifically, a strong program also asks about your menstrual and hormonal status, because perimenopause, PCOS, contraception, and pregnancy plans all change the calculus. If a provider never asks whether you could become pregnant or what birth control you use, that is a gap, not a convenience.

Which medications are used — and the approved-use distinction that matters

The medications at the center of modern medical weight loss for women fall into two regulatory buckets, and the difference affects both your eligibility and your coverage. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults who meet the BMI criteria. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes; prescribing either for weight loss alone is off-label use.

Off-label prescribing is legal and common, but it has consequences. Insurance is far less likely to cover a diabetes drug used for weight, manufacturer savings programs are tied to specific approved indications, and the drug's Prescribing Information describes its studied population for its approved use, not for weight loss on its own. When a provider mentions Ozempic or Mounjaro for weight, that is a signal to ask directly whether they mean the diabetes product used off-label, and what that means for your cost and coverage.

NIDDK notes that anti-obesity medications work in different ways and that response varies between individuals; the best choice depends on your health profile, other conditions, and tolerance, which is exactly why a prescriber's evaluation matters. Older approved options beyond the GLP-1 class also exist, and NIDDK's overview is the authoritative starting point for the full list of prescription medicines used to treat overweight and obesity.

FDA-approved use of the four most-discussed injectables (verify any product on Drugs@FDA)
Product	Active ingredient	FDA-approved for	For weight loss it is	Women's-health note
Wegovy	Semaglutide 2.4 mg	Chronic weight management	On-label	No oral-contraceptive interaction warning
Zepbound	Tirzepatide	Chronic weight management	On-label	Label warns it can reduce oral contraceptive effectiveness
Ozempic	Semaglutide	Type 2 diabetes	Off-label	No oral-contraceptive interaction warning
Mounjaro	Tirzepatide	Type 2 diabetes	Off-label	Label warns it can reduce oral contraceptive effectiveness

Do you qualify? The FDA BMI criteria in plain language

Eligibility for the FDA-approved weight-management drugs is written into the Indications section of each label, and the threshold is the same idea across them. You may qualify if your body mass index is 30 or higher, which is the clinical definition of obesity. You may also qualify at a BMI of 27 or higher — the overweight range — if you also have at least one weight-related health condition.

The label gives examples of those weight-related conditions: high blood pressure (hypertension), abnormal cholesterol or triglycerides (dyslipidemia), and type 2 diabetes, among others. This 27-with-a-condition pathway is why two women at the same weight can have different eligibility: the one with treated hypertension or diabetes may meet the criteria at a BMI where the other does not.

A prescriber applies these criteria to your specific numbers and history, and BMI is a screening tool rather than a complete measure of health, so the clinical evaluation still governs the final decision. If a telehealth intake never asks your height, weight, or relevant conditions, it cannot be applying the label criteria — which is a reason to be skeptical of how the prescription is being issued.

How telehealth delivers medical weight loss

Telehealth has become the most common on-ramp to these programs, and the legitimate path has a specific shape. You complete an intake with your medical history and measurements, you consult with a clinician licensed in your state (by video, phone, or a reviewed asynchronous questionnaire depending on the platform and state law), and if a prescription is appropriate it is sent to a licensed pharmacy that dispenses to you. The prescriber-and-pharmacy structure is what makes it a medical service rather than a storefront.

A legitimate provider verifies your identity and state of residence because prescribing requires a clinician licensed where you are, screens for contraindications and drug interactions, and provides a way to reach a clinician about side effects and dose changes. Titration schedules, refill logic, and follow-up check-ins are handled by that clinical relationship, not left to you to figure out alone.

The warning sign is any site that skips the prescriber entirely or treats the consult as a formality that always ends in a sale. The FDA has warned about unapproved and counterfeit GLP-1 products sold outside the legitimate supply chain. If a website offers semaglutide or tirzepatide with no prescription, no licensed pharmacy, or shipping from unclear origins, treat it as a safety risk rather than a bargain. Our guides on getting these medications online — including how-to-get-wegovy-online and how-to-get-zepbound-online — walk through the legal path in more detail.

The real cost structure: five payment paths, not one price

The single most common mistake in shopping for medical weight loss is expecting one price. There isn't one. What you pay depends entirely on which of several payment paths applies to you, and the same drug can differ severalfold between them. The honest way to compare providers is to figure out which path you're on before you look at any advertised number.

Because manufacturers change list prices, savings-card terms, and self-pay programs over time, the only reliable source for a current figure is the manufacturer's own coverage and savings page for that specific drug. Lilly publishes coverage and savings information for Zepbound and Mounjaro; Novo Nordisk and NovoCare publish it for Wegovy and Ozempic. Any third party quoting you a fixed dollar amount without pointing to those pages is guessing or marketing.

The table below is a structural map, not a price list. Use it to identify your path, then verify the live number on the manufacturer page linked in Sources. Note that off-label use of a diabetes product can disqualify you from a weight-management savings program, and that coverage for weight-management drugs specifically is a common exclusion in commercial and government plans.

Payment paths for branded weight-management medication — verify live figures on the manufacturer's savings page
Payment path	What it is	What drives your cost	Where to verify
Insurance-covered	Your commercial or employer plan covers the branded drug	Formulary tier, prior authorization, whether the plan covers weight-management drugs at all	Your plan documents plus NovoCare or Lilly coverage checker
Manufacturer savings card	A discount for people with commercial insurance on an approved indication	Commercial insurance (not Medicare/Medicaid), a monthly cap, the approved use	Save on Wegovy / Zepbound coverage & savings page
Manufacturer self-pay	Buying the branded drug directly from the manufacturer without insurance	A fixed self-pay price the manufacturer sets and updates	Manufacturer's own self-pay / savings page
Cash at pharmacy	No insurance, paying the pharmacy for the branded drug	Pharmacy pricing and the manufacturer list price	NovoCare / Lilly savings pages
Compounded	A non-FDA-approved copy from a compounding pharmacy	Pharmacy pricing, which is not standardized, plus regulatory risk	FDA warnings; not a manufacturer product

Compounded semaglutide and tirzepatide: cheaper, but not FDA-approved

Compounded versions of semaglutide and tirzepatide are often marketed as a lower-cost alternative, and understanding what they are is essential before you compare on price. Compounded drugs are mixed by a pharmacy rather than manufactured and approved as finished products. They are not FDA-approved, which means the agency has not reviewed those specific compounded products for safety, effectiveness, or quality the way it reviews Wegovy or Zepbound.

The FDA has warned about unapproved and compounded GLP-1 products, including concerns about dosing errors and products of uncertain origin. Availability of legally compounded versions has also shifted with the branded drugs' shortage status, because the rules that allow compounding of a drug in shortage change when that shortage resolves. A compounding option that was widely offered at one point may not be permitted later, which is why the compounded market is less stable than the branded one.

None of this means every compounding pharmacy is unsafe, but it does mean the price gap comes with a trade-off in oversight, and that the trade-off is not always disclosed clearly in marketing. If you are weighing a compounded option, our guides on compounded-vs-brand-tirzepatide and compounded-tirzepatide-for-women lay out the specific differences, and any decision belongs with a licensed prescriber who knows your history.

Why perimenopause changes the weight-loss equation

Weight gain around the midsection in the forties and fifties is one of the most common reasons women look into medical weight loss, and it is not simply a matter of willpower or slowing down. The hormonal shifts of perimenopause and menopause change where the body stores fat, favoring abdominal fat, and coincide with age-related loss of muscle, which lowers resting energy needs. That combination makes the same eating and activity habits produce different results than they did a decade earlier.

This matters for a weight-loss program in two ways. First, an anti-obesity medication addresses appetite and metabolic drivers but does not reverse the hormonal transition itself, so expectations should be set accordingly. Second, some women are simultaneously considering menopause hormone therapy for symptoms like hot flashes and sleep disruption. Hormone therapy is not a weight-loss treatment — ACOG's patient guidance frames it as symptom management — but the two decisions often happen in the same season of life and deserve to be coordinated by clinicians who see the whole picture.

Because these questions overlap, we cover them separately in depth. Our page on glp1-vs-hrt-for-menopause-weight compares what each does and does not do, and for symptom-driven questions, ACOG's hormone therapy FAQ (linked in Sources) is the authoritative patient reference. Deciding between them, or using them for different purposes at once, is a conversation for your prescriber rather than a marketing claim.

PCOS, insulin resistance, and weight

Polycystic ovary syndrome is one of the most relevant hormonal conditions for medical weight loss because it commonly involves insulin resistance, which makes weight harder to lose and easier to regain. For many women with PCOS, weight, blood sugar regulation, and menstrual irregularity are tangled together, and the GLP-1 class acts directly on the appetite and metabolic pathways involved.

That biological overlap is why GLP-1 medications come up frequently in PCOS discussions. It is important to be precise, though: these drugs are FDA-approved for weight management or diabetes, and their use specifically for PCOS is a clinical decision your prescriber makes based on your profile, not a separate approved indication. Whether the goal is weight, metabolic health, or fertility planning changes the conversation substantially, especially since these medications are not used during pregnancy.

If PCOS is your reason for exploring medical weight loss, the evaluation should capture your full metabolic and reproductive picture rather than just a BMI number. Our dedicated guide on glp1-for-pcos goes deeper into how the medications interact with insulin resistance and what to raise with a prescriber, including the pregnancy and contraception considerations that follow.

The birth control interaction women are told about too late

Here is a difference that a generic weight-loss page will not tell you and that matters specifically for women of reproductive age: tirzepatide can reduce the effectiveness of oral contraceptives. This is stated in the Prescribing Information for the tirzepatide products, Zepbound and Mounjaro, and it means the pill may not work as reliably when you start tirzepatide or increase the dose.

Because of that, the tirzepatide labeling advises additional precautions around contraception for a period after starting and after each dose increase — the kind of specific guidance your prescriber should give you directly. Semaglutide, the active ingredient in Wegovy and Ozempic, does not carry this oral-contraceptive warning, which is a genuine point of difference between the two drug families for a woman who relies on the pill.

This single fact can reasonably tip a medication choice, or at least a contraception plan, and it is a concrete reason not to source these drugs outside a real clinical relationship. A prescriber who knows you use oral contraception can flag it before you start; an unsupervised online seller will not. Our guide on glp1-and-birth-control covers the practical steps in more detail.

Monitoring, side effects, and what to expect over time

The supervised part of medical weight loss earns its name in the monitoring. GLP-1 and GIP/GLP-1 medications are started low and increased gradually because the most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and slow titration reduces them. A supervising clinician decides when to advance the dose and when to hold, which is not something a one-time prescription can do.

Labels for this class also carry more serious warnings that a prescriber screens for and monitors, which is part of why the evaluation and follow-up exist rather than being optional add-ons. This is genuinely medical care, and the value of a program is partly in the clinician being reachable when something changes. A provider that cannot be reached about side effects between refills is selling a product without the supervision the category requires.

Results and tolerance vary between individuals, as NIDDK notes, and weight regain is common if medication stops without a maintenance plan, which is why the lifestyle and behavior components are not filler. When you compare programs, the quality of monitoring and the ease of reaching a clinician are worth as much attention as the headline price, because they are what separate a medical program from a transaction.

How to compare providers licensed in your state

Once you understand the category, comparing providers becomes a checklist rather than a leap of faith. A legitimate provider confirms your state and identity, runs a real intake with your measurements and history, uses a prescriber licensed where you live, and dispenses through a licensed pharmacy. It is transparent about whether it offers FDA-approved branded drugs, off-label diabetes products, or compounded products, and it points you to the manufacturer's savings page for real pricing rather than quoting an inflated or vague number.

Match the provider to your payment path. If you have commercial insurance, prioritize one that will handle prior authorization and check formulary coverage. If you are self-paying, compare the total cost including consults and follow-ups, not just the medication line, and confirm whether the price is for a branded or compounded product — because those are not the same thing. Ask directly about the birth control interaction if you use oral contraception and whether the program is set up for perimenopause or PCOS if those apply to you.

Our provider comparisons and category rankings are designed for exactly this step: to let you compare telehealth options licensed in your state on the factors that actually differ. This site does not sell or prescribe anything — the medication decision is between you and a licensed clinician — but a clear comparison of who offers what, and on what terms, is the fastest way to avoid the sellers you should not trust.

When to see a healthcare provider

A website that sells semaglutide or tirzepatide with no prescription, no clinician consult, and no licensed pharmacy — a signal for counterfeit or unapproved product the FDA has warned about. —
Any provider quoting a fixed 'price' without pointing you to the manufacturer's savings page, since list prices, savings-card terms, and self-pay programs change over time. —
A program that writes a prescription with no evaluation, no labs, no dose titration plan, and no way to reach a clinician about side effects between refills. —
Marketing that blurs compounded and FDA-approved products as if they were the same thing — compounded semaglutide and tirzepatide are not FDA-approved. —
A telehealth intake for tirzepatide that never asks about oral contraception, despite the label's warning that tirzepatide can reduce contraceptive effectiveness. —
Pressure tactics, urgency countdowns, or 'no evaluation needed' promises — legitimate medical care confirms your state, identity, and history first. —

If symptoms are severe or sudden, contact your primary-care provider, OB/GYN, or a telehealth clinician for same-day evaluation. Browse providers with same-day visits.

Affiliate link Advertiser Disclosure: This site is reader-supported. We may earn an affiliate commission when you sign up for a service through links on our site. This does not influence our editorial recommendations or medical reviews. Read our full disclosure.

Frequently asked questions

What is the difference between medical weight loss and just buying a GLP-1?: Medical weight loss is a supervised program: a clinical evaluation, a prescription chosen for your situation, ongoing monitoring of dose and side effects, and lifestyle support. NIDDK treats the medication as an addition to diet and activity, not a substitute. Buying a drug with no evaluation, no licensed pharmacy, and no follow-up is a transaction, not care — and often a safety risk.
Do I qualify for FDA-approved weight-loss medication?: The FDA label criteria are a BMI of 30 or higher, or a BMI of 27 or higher combined with at least one weight-related condition such as high blood pressure, abnormal cholesterol, or type 2 diabetes. A prescriber applies these to your actual measurements and history. BMI is a screening tool, so the clinical evaluation still governs the final decision.
Which weight-loss drug is right if I take birth control pills?: This is a real point of difference. Tirzepatide (Zepbound and Mounjaro) can reduce oral contraceptive effectiveness according to its FDA label, and the labeling advises extra contraceptive precautions after starting and after dose increases. Semaglutide (Wegovy and Ozempic) does not carry that warning. Raise your contraception with a prescriber before choosing — an unsupervised seller will not flag it.
How much does a medical weight-loss program cost?: There is no single price. Cost depends on your payment path: insurance coverage, a manufacturer savings card, manufacturer self-pay, cash at a pharmacy, or a non-FDA-approved compounded product. Because manufacturers change prices, the only reliable current figure comes from the drug maker's own savings page — Lilly for Zepbound and Mounjaro, Novo Nordisk and NovoCare for Wegovy and Ozempic.
Is compounded semaglutide or tirzepatide safe and legal?: Compounded versions are mixed by a pharmacy and are not FDA-approved, meaning those specific products were not reviewed for safety, effectiveness, or quality the way branded drugs are. The FDA has warned about unapproved and compounded GLP-1 products, and their legal availability has shifted with the branded drugs' shortage status. Any compounded decision belongs with a licensed prescriber who knows your history.
Can these medications help with PCOS or perimenopause weight gain?: PCOS often involves insulin resistance, which the GLP-1 class acts on, and perimenopause shifts fat storage and metabolism. The drugs are FDA-approved for weight management or diabetes, not for PCOS or menopause specifically, so any such use is a clinical decision by your prescriber. Hormone therapy, per ACOG, manages menopause symptoms and is not a weight-loss treatment; coordinate these decisions with clinicians who see the full picture.
Can I get weight-loss medication online without a prescription?: No — and any site offering it without one is a warning sign. The legitimate telehealth path requires a consult with a clinician licensed in your state and dispensing through a licensed pharmacy. The FDA has warned about counterfeit and unapproved GLP-1 products sold outside the legal supply chain. No prescription, no licensed pharmacy, or unclear shipping origin means treat it as a safety risk, not a deal.
Is Ozempic or Mounjaro approved for weight loss?: No. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, so using either for weight loss alone is off-label. The FDA-approved weight-management versions are Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Off-label use is legal but affects insurance coverage and eligibility for manufacturer savings programs, so ask a provider exactly which product they mean.

Primary sources

ClearHormones publishes editorial health information for education only — not medical advice.